The Health Resources & Services Administration warned drugmakers AbbVie and Amgen Oct. 17 they are in violation of a federal program by overcharging drug sales.
Read the full post on Becker's Hospital Review - Healthcare News
AbbVie, Amgen are violating 340B program, HRSA says
